{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-229453","form_type":"8-K","ticker":null,"cik":"0001305253","company_name":"Eiger BioPharmaceuticals, Inc.","filed_at":"2024-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.043700+00:00","generated_at":"2026-05-30T23:04:14.683762+00:00","sec_items":["1.03","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Eiger BioPharmaceuticals Chapter 11 liquidation plan effective; common stock cancelled","bullets":["September 30, 2024 effective date: all outstanding common shares cancelled and no longer valid.","Equity holders entitled to pro rata share of Existing Equity Interest Recovery Pool, if any.","Company intends to file Form 15 to immediately suspend SEC reporting obligations.","Plan confirmed by Bankruptcy Court on September 5, 2024; earlier Chapter 11 filing on April 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-229453","json":"https://secwatch.observer/filing/0001193125-24-229453.json","markdown":"https://secwatch.observer/filing/0001193125-24-229453.md","text":"https://secwatch.observer/filing/0001193125-24-229453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524229453/0001193125-24-229453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524229453/d850551d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T23:04:14.683762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c987d841f02db7a721b5e34dacf9410d9c0c1e9","claim":"Eiger BioPharmaceuticals, Inc. entered chapter 11 in United States Bankruptcy Court for the Northern District of Texas (petition 2024-04-01).","evidence_excerpt":"on April 1, 2024, Eiger BioPharmaceuticals, Inc. (the “ Company ”) and its direct subsidiaries (together the “ Debtors ”) filed voluntary petitions for relief under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Northern District of Texas (the “ Bankruptcy Court ”) under the caption In re Eiger BioPharmaceuticals, Inc., et al , Case No. 24-80040.","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1305253/000119312524229453/0001193125-24-229453-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the Northern District of Texas"},{"label":"Petition","value":"2024-04-01"}],"fact_type":"distress_event"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}